About
About MYUNGMOON Pharm co.,Ltd
MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervous system products, female hormone products, osteoporotic therapeutics, urogentital agents, adrenocortical hormone products, oncology agents, other preparations, and anti-obesity agents for pharmacotherapy. The company also provides OTC products, such as antinausants, genitourinary system products, anti gum disease products, hepatics, parasiticides, cathartic, antidiarrheal agents, digestive system products, multiple vitamin products, eye nutrition products, eye drops, blood circulation products, circulatory solvents, skin external preparations, and topical analgesic products. In addition, it offers health supplements, quasi drugs, and blended juices. MYUNGMOON Pharm co.,Ltd was founded in 1983 and is headquartered in Seoul, South Korea.
Visit company website
5 years, 4 months ago
MYUNGMOON Pharm co.,Ltd is currently in a long term downtrend where the price is trading 6.6% below its 200 day moving average.
From a valuation standpoint, the stock is 86.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.2.
MYUNGMOON Pharm co.,Ltd's total revenue sank by 16.4% to $32B since the same quarter in the previous year.
Its net income has increased by 35.6% to $-8B since the same quarter in the previous year.
Finally, its free cash flow fell by 215.3% to $-11B since the same quarter in the previous year.
Based on the above factors, MYUNGMOON Pharm co.,Ltd gets an overall score of 2/5.